Effects of L-arginine Supplementation in severe fever with thrombocytopenia syndrome patients

Randomized controlled trial of administration of arginine hydrochloride injection on severe fever with thrombocytopenia syndrome patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17012288

Enrollment

Unknown

Registered

2017-08-08

Start date

2017-08-10

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe fever with thrombocytopenia syndrome

Interventions

Arginine treatment group:Symptomatic treatment + arginine treatment

Placebo group:Symptomatic treatment + glucose injection

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: patients who have to meet all of following items: 1. Clinical diagnosis: diagnostic criteria in accordance with the Ministry of Health issued by the "fever with thrombocytopenia syndrome prevention and control guidelines" implementation. Mainly based on epidemiological history (epidemic season in the hills, forest, mountain and other places of work, life or travel history or 2 weeks before the onset of tick bites history), fever and other clinical manifestations and peripheral platelets or white blood cells decreased; 2. Pathogen diagnosis: SFTSV virus nucleic acid detection positive; 3. platelet count between 30-80*10^9/L; 4. Aged between 18-80 years old, male and female

Exclusion criteria

Exclusion criteria: patients who meet any one of the following criteria will be excluded: 1. Time between admission and the disease onset is more than 7 days; 2. With high chlorine acidosis, renal insufficiency and anuria and other contraindications; 3. Receiving antiviral drugs, immunomodulatory treatment within 6 months; 4. Combined with other pathogen infections, such as HIV, syphilis, Rickettsia, Lyme disease spiral or bar Biscuits and other pathogens that can cause similar symptoms; 5. Patients with chronic basic diseases such as cancer, tuberculosis, nephropathy; 6. Recent use of antiplatelet agents or antiallergic drugs; 7. Pregnant or lactating women; 8. No or unwilling signed informed consent; 9. Patients who are participating in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Mortality rate, severity rate, rate of improvement;Viral Loads;hepatic and renal function;	—

Secondary

Measure	Time frame
Platelet function;Immunological index;Bleeding and vascular leakage symptoms;Routine laboratory examination;	—

Countries

China

Contacts

Public ContactWei Liu

State Key Laboratory of Pathogen and Biosecurity

lwbime@163.com+86 13810739767

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026